# SARS‐CoV‐2 Antibody Levels and Infections in Multiple Vaccinated Employees Over Time

**Authors:** Ingrid Sander, Sabine Kespohl, Alexandra Beine, Kerstin Belting, Jürgen Bünger, Simon Weidhaas, Ingolf Hosbach, Christian Eisenhawer, Jan Gleichenhagen, Philipp Göcke, Thomas Brüning, Monika Raulf

PMC · DOI: 10.1002/jmv.70628 · Journal of Medical Virology · 2025-10-18

## TL;DR

This study tracked antibody levels in vaccinated individuals over 3 years and found that while vaccination boosts immunity, Omicron variant antibodies decline faster and are less effective.

## Contribution

The study provides longitudinal data on antibody dynamics after repeated vaccination and infection with SARS-CoV-2 variants.

## Key findings

- IgG levels against both Wuhan and Omicron variants increased with each vaccination or infection.
- Antibodies against the Wuhan type had longer half-lives than those against Omicron.
- Most vaccinated individuals still experienced breakthrough infections despite rising antibody levels.

## Abstract

This prospective cohort study aimed to monitor the humoral immune response to SARS‐CoV‐2 proteins over 3 years in relation to repeated vaccination or infection. Quantitative immunoassays traceable to international IgG units were used to measure and compare IgG levels against Wuhan type and Omicron spike‐S1 and nucleocapsid proteins over 3 years. In addition, the Euroimmun‐N‐test was used to determine positive IgG values against the nucleocapsid. A total of 1223 serum samples from 126 participants without evidence of COVID‐19 at enrollment were analyzed and used to calculate antibody half‐lives following vaccination or infection, as reported by the questionnaire. Antibody levels and half‐life against both variants of the spike S1 protein increased significantly with each additional vaccination or after infection. IgG against the Wuhan type was, on average, three times higher than against the Omicron variant. The half‐lives of antibodies against the Wuhan type after the second and third vaccinations and after infection were significantly longer than those of IgG against the Omicron variant. Two‐thirds of the cohort reported COVID‐19 infection, detected with a sensitivity of 70% by the quantitative nucleocapsid IgG assay and 83% by the Euroimmun‐N‐test. The level of anti‐nucleocapsid‐IgG after infection in the vaccinated cohort was significantly lower than anti‐S1‐IgG and also lower than in unvaccinated infected persons. Despite repeated vaccinations and progressively increasing IgG antibody levels targeting the spike protein, most of the cohort reported breakthrough infections, possibly due to the lower concentration and reduced half‐life of antibodies against the Omicron variant.

## Linked entities

- **Diseases:** COVID-19 (MONDO:0100096)

## Full-text entities

- **Diseases:** COVID-19 (MESH:D000086382), Infections (MESH:D007239)
- **Species:** Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12535279/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12535279/full.md

## References

30 references — full list in the complete paper: https://tomesphere.com/paper/PMC12535279/full.md

---
Source: https://tomesphere.com/paper/PMC12535279